Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Published 2018 View Full Article

Authors

Keywords

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume 79, Issue 2, Pages 302-314.e6

Publisher

Elsevier BV

Online

2018-04-14

DOI

10.1016/j.jaad.2018.04.012

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Ask a Question. Answer a Question.